MedImmune to hire 800 in pipeline push

With plans to double the number of experimental therapies in its pipeline by 2010, MedImmune is laying plans to hire 800 new staffers by the end of this year, according to a report in the Washington Business Journal. That's a 25 percent increase in its workforce, which also swelled after AstraZeneca bought the Gaitherburg, MD-based developer and combined its operations with the UK's Cambridge Antibody Technology Group. Many of these new hires will be headed for the research department, which has ambitious plans for fast growth. MedImmune has outlined plans to provide 25 percent of AstraZeneca's late-stage therapies by 2010.

- read the report in the Washington Business Journal

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.